Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Xerosis, characterized by dry, rough skin, causes discomfort and aesthetic concerns, necessitating effective treatment. Traditional treatments often show limited efficacy, prompting the need for innovative therapies. This study highlights the efficacy of microbiome therapeutic LP51, derived from a healthy vaginal microbiome, in improving xerosis. A double-blind clinical trial involving 43 subjects with dry inner arm skin compared the effects of a 2.9% LP51 extract formulation to a placebo over 4 weeks. The LP51 group exhibited a significant increase in stratum corneum hydration (10.0 A.U.) compared to the placebo group (4.8 A.U.) and a 21.4% decrease in transepidermal water loss (TEWL), whereas the placebo group showed no significant change. LP51 also demonstrated benefits in enhancing skin hydration, improving the skin barrier, and exhibited anti-atopic, anti-inflammatory, and antioxidant properties. Safety was confirmed through in vitro cytotoxicity tests. These effects are attributed to the microbiome-safe component in LP51 and its role in improving xerosis, reflected by an increase in the xerosis-microbiome index, defined by the Firmicutes/Actinobacteria ratio. These findings position microbiome therapeutic LP51 as a promising novel treatment for xerosis.

Details

Title
Clinical Potential of Novel Microbial Therapeutic LP51 Based on Xerosis-Microbiome Index
Author
Kim, Sukyung 1 ; Md Abdur Rahim 1 ; Tajdozian, Hanieh 2   VIAFID ORCID Logo  ; Barman, Indrajeet 2   VIAFID ORCID Logo  ; Hyun-A Park 1 ; Yoon, Youjin 2   VIAFID ORCID Logo  ; Jo, Sujin 2 ; Lee, Soyeon 3   VIAFID ORCID Logo  ; Md Sarower Hossen Shuvo 2   VIAFID ORCID Logo  ; Sung Hae Bae 1 ; Lee, Hyunji 1 ; Ju, Sehee 1 ; Chae-eun Park 2 ; Ho-Kyoung, Kim 1 ; Han, Jeung Hi 4 ; Ji-Woong, Kim 4   VIAFID ORCID Logo  ; Yoon, Sung geon 4 ; Jae Hong Kim 4 ; Choi, Yang Gyu 4 ; Lee, Saebim 1 ; Seo, Hoonhee 1 ; Ho-Yeon, Song 2 

 Human Microbiome Medical Center (HM·MRC), Soonchunhyang University, 22, Soonchunhyang-ro, Sinchang-myeon, Asan-si 31538, Chungnam, Republic of Korea; [email protected] (S.K.); [email protected] (M.A.R.); [email protected] (H.T.); [email protected] (I.B.); [email protected] (H.-A.P.); [email protected] (Y.Y.); [email protected] (S.J.); [email protected] (M.S.H.S.); [email protected] (S.H.B.); [email protected] (H.L.); [email protected] (S.J.); [email protected] (C.-e.P.); [email protected] (H.-K.K.); [email protected] (S.L.) 
 Human Microbiome Medical Center (HM·MRC), Soonchunhyang University, 22, Soonchunhyang-ro, Sinchang-myeon, Asan-si 31538, Chungnam, Republic of Korea; [email protected] (S.K.); [email protected] (M.A.R.); [email protected] (H.T.); [email protected] (I.B.); [email protected] (H.-A.P.); [email protected] (Y.Y.); [email protected] (S.J.); [email protected] (M.S.H.S.); [email protected] (S.H.B.); [email protected] (H.L.); [email protected] (S.J.); [email protected] (C.-e.P.); [email protected] (H.-K.K.); [email protected] (S.L.); Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, 31, Suncheonhyang 6-gil, Dongnam-gu, Cheonan-si 31151, Chungnam, Republic of Korea; [email protected] 
 Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, 31, Suncheonhyang 6-gil, Dongnam-gu, Cheonan-si 31151, Chungnam, Republic of Korea; [email protected] 
 Materials Science Research Institute, LABIO, Inc., 184 Gasan Digital 2-ro, Geumcheon-gu, Seoul 08501, Republic of Korea; [email protected] (J.H.H.); [email protected] (J.-W.K.); [email protected] (S.g.Y.); [email protected] (J.H.K.); [email protected] (Y.G.C.) 
First page
2029
Publication year
2024
Publication date
2024
Publisher
MDPI AG
e-ISSN
20734409
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3143984856
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.